See more : Allkem Limited (AKE.TO) Income Statement Analysis – Financial Results
Complete financial analysis of Johnson & Johnson (JNJ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Johnson & Johnson, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
You may be interested
- Salmon Evolution ASA (SALME.OL) Income Statement Analysis – Financial Results
- Fidelity Holding Corp. (FDHC) Income Statement Analysis – Financial Results
- Selina Hospitality PLC (SLNAW) Income Statement Analysis – Financial Results
- MagForce AG (MF6.DE) Income Statement Analysis – Financial Results
- Chesser Resources Limited (CHZ.AX) Income Statement Analysis – Financial Results
Johnson & Johnson (JNJ)
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 85.16B | 79.99B | 78.74B | 82.58B | 82.06B | 81.58B | 76.45B | 71.89B | 70.07B | 74.33B | 71.31B | 67.22B | 65.03B | 61.59B | 61.90B | 63.75B | 61.10B | 53.32B | 50.51B | 47.35B | 41.86B | 36.30B | 33.00B | 29.14B | 27.47B | 23.66B | 22.63B | 21.62B | 18.84B | 15.73B | 14.14B | 13.75B | 12.45B | 11.23B | 9.76B | 9.00B | 8.01B | 7.00B | 6.42B |
| Cost of Revenue | 26.55B | 24.60B | 23.40B | 28.43B | 27.56B | 27.09B | 25.35B | 21.69B | 21.54B | 22.75B | 22.34B | 21.66B | 20.36B | 18.79B | 18.45B | 18.51B | 17.75B | 15.06B | 13.95B | 13.42B | 12.18B | 10.45B | 9.54B | 7.35B | 7.00B | 6.19B | 6.09B | 6.01B | 5.38B | 4.58B | 4.17B | 4.12B | 3.71B | 3.46B | 3.07B | 2.90B | 2.60B | 2.35B | 2.34B |
| Gross Profit | 58.61B | 55.39B | 55.34B | 54.16B | 54.50B | 54.49B | 51.10B | 50.21B | 48.54B | 51.59B | 48.97B | 45.57B | 44.67B | 42.80B | 43.45B | 45.24B | 43.34B | 38.27B | 36.56B | 33.93B | 29.69B | 25.85B | 23.47B | 21.79B | 20.47B | 17.47B | 16.54B | 15.61B | 13.46B | 11.16B | 9.96B | 9.64B | 8.74B | 7.77B | 6.69B | 6.10B | 5.41B | 4.65B | 4.08B |
| Gross Profit Ratio | 68.82% | 69.25% | 70.28% | 65.58% | 66.42% | 66.79% | 66.84% | 69.84% | 69.27% | 69.40% | 68.67% | 67.78% | 68.69% | 69.49% | 70.20% | 70.96% | 70.95% | 71.76% | 72.38% | 71.65% | 70.91% | 71.22% | 71.11% | 74.79% | 74.53% | 73.83% | 73.11% | 72.21% | 71.46% | 70.92% | 70.48% | 70.06% | 70.19% | 69.17% | 68.58% | 67.77% | 67.52% | 66.37% | 63.50% |
| Research & Development | 15.05B | 14.14B | 14.28B | 12.34B | 11.36B | 10.78B | 10.55B | 9.10B | 9.05B | 8.49B | 8.18B | 7.67B | 7.55B | 6.84B | 7.17B | 7.76B | 7.68B | 7.13B | 6.31B | 5.20B | 4.68B | 3.96B | 3.59B | 2.93B | 2.60B | 2.27B | 2.14B | 0.00 | 0.00 | 1.28B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 20.11B | 19.05B | 20.12B | 22.08B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 20.11B | 19.05B | 20.12B | 22.08B | 22.18B | 22.54B | 21.42B | 19.95B | 21.20B | 21.95B | 21.83B | 20.87B | 20.97B | 19.42B | 19.80B | 21.49B | 20.45B | 17.43B | 16.88B | 15.86B | 14.13B | 12.22B | 11.99B | 10.88B | 10.50B | 8.91B | 8.72B | 10.30B | 9.10B | 6.35B | 6.95B | 6.80B | 6.08B | 5.30B | 4.62B | 4.30B | 3.85B | 3.39B | 2.99B |
| Other Expenses | 0.00 | 500.00M | -526.00M | -2.90B | -2.53B | -1.41B | -183.00M | -484.00M | 2.06B | 70.00M | -2.50B | -1.63B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 35.56B | 33.18B | 34.40B | 34.42B | 33.53B | 33.32B | 31.97B | 29.04B | 30.25B | 30.45B | 30.01B | 28.53B | 28.52B | 26.27B | 26.97B | 29.25B | 28.13B | 24.56B | 23.19B | 21.06B | 18.82B | 16.17B | 15.58B | 15.32B | 14.55B | 12.42B | 11.92B | 11.31B | 9.95B | 8.35B | 7.57B | 7.36B | 6.57B | 5.78B | 5.03B | 4.70B | 4.20B | 3.66B | 3.24B |
| Cost & Expenses | 61.81B | 57.78B | 57.80B | 62.85B | 61.09B | 60.41B | 57.33B | 50.73B | 51.79B | 53.19B | 52.36B | 50.19B | 48.88B | 45.06B | 45.42B | 47.76B | 45.88B | 39.62B | 37.14B | 34.49B | 30.99B | 26.62B | 25.12B | 22.66B | 21.55B | 18.61B | 18.01B | 17.32B | 15.33B | 12.93B | 11.74B | 11.48B | 10.28B | 9.24B | 8.10B | 7.60B | 6.80B | 6.02B | 5.58B |
| Interest Income | 1.26B | 490.00M | 53.00M | 111.00M | 357.00M | 611.00M | 385.00M | 368.00M | 128.00M | 67.00M | 74.00M | 64.00M | 91.00M | 107.00M | 90.00M | 361.00M | 452.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 772.00M | 276.00M | 183.00M | 201.00M | 318.00M | 1.01B | 934.00M | 726.00M | 552.00M | 533.00M | 482.00M | 532.00M | 571.00M | 348.00M | 451.00M | 435.00M | 296.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 7.49B | 6.97B | 7.39B | 7.23B | 7.01B | 6.93B | 5.64B | 3.75B | 3.75B | 3.90B | 4.10B | 3.67B | 3.16B | 2.94B | 2.77B | 2.83B | 2.78B | 2.18B | 2.09B | 2.12B | 1.87B | 1.66B | 1.61B | 1.52B | 1.44B | 1.25B | 1.07B | 1.01B | 857.00M | 724.00M | 617.00M | 560.00M | 493.00M | 474.00M | 414.00M | 391.00M | 356.00M | 275.20M | 250.50M |
| EBITDA | 23.73B | 27.17B | 30.93B | 27.50B | 28.27B | 28.10B | 24.54B | 24.92B | 22.12B | 25.03B | 23.16B | 17.96B | 16.05B | 20.35B | 18.96B | 20.20B | 16.36B | 15.77B | 15.61B | 15.02B | 13.27B | 11.82B | 9.78B | 8.08B | 7.59B | 6.96B | 5.62B | 5.46B | 4.42B | 3.58B | 2.93B | 2.78B | 2.65B | 2.63B | 2.08B | 1.70B | 1.47B | 1.79B | 985.40M |
| EBITDA Ratio | 27.86% | 37.71% | 35.38% | 29.27% | 26.96% | 27.64% | 25.95% | 30.16% | 27.15% | 28.68% | 27.40% | 27.07% | 29.93% | 26.84% | 27.51% | 27.84% | 32.86% | 29.58% | 30.91% | 31.72% | 31.71% | 32.57% | 29.63% | 27.73% | 27.64% | 29.41% | 24.81% | 25.24% | 23.45% | 22.72% | 20.73% | 20.24% | 21.32% | 23.45% | 21.33% | 18.88% | 18.29% | 25.50% | 15.35% |
| Operating Income | 23.41B | 23.19B | 20.47B | 16.95B | 15.12B | 15.62B | 14.20B | 17.93B | 15.28B | 17.42B | 15.43B | 14.53B | 16.31B | 13.59B | 14.26B | 14.92B | 17.30B | 13.60B | 13.52B | 12.90B | 11.40B | 10.16B | 8.18B | 6.57B | 6.15B | 5.71B | 4.55B | 4.45B | 3.56B | 2.85B | 2.31B | 2.22B | 2.16B | 2.16B | 1.67B | 1.31B | 1.11B | 1.51B | 734.90M |
| Operating Income Ratio | 27.49% | 28.99% | 26.00% | 20.52% | 18.42% | 19.15% | 18.57% | 24.94% | 21.80% | 23.44% | 21.64% | 21.61% | 25.08% | 22.06% | 23.03% | 23.40% | 28.31% | 25.50% | 26.76% | 27.24% | 27.24% | 27.99% | 24.77% | 22.53% | 22.38% | 24.14% | 20.10% | 20.57% | 18.90% | 18.12% | 16.37% | 16.16% | 17.36% | 19.23% | 17.09% | 14.53% | 13.84% | 21.57% | 11.44% |
| Total Other Income/Expenses | -8.35B | -2.85B | -1.77B | -3.24B | 2.21B | 2.38B | -1.22B | -1.09B | 907.00M | -574.00M | 38.00M | -3.26B | -3.79B | 420.00M | -908.00M | 760.00M | -1.93B | 990.00M | 137.00M | 482.00M | -563.00M | -387.00M | -277.00M | 303.00M | -108.00M | -846.00M | -46.00M | -270.00M | -194.00M | -126.00M | -62.00M | -70.00M | -126.00M | -369.00M | -147.00M | -8.00M | -16.00M | -592.80M | 164.30M |
| Income Before Tax | 15.06B | 19.36B | 19.18B | 16.50B | 17.33B | 18.00B | 17.67B | 19.80B | 19.20B | 20.56B | 15.47B | 13.78B | 12.36B | 16.95B | 15.76B | 16.93B | 13.28B | 14.59B | 13.66B | 12.84B | 10.31B | 9.29B | 7.90B | 6.62B | 5.75B | 4.27B | 4.58B | 4.03B | 3.32B | 2.68B | 2.33B | 2.21B | 2.04B | 1.62B | 1.51B | 1.40B | 1.19B | 390.80M | 899.20M |
| Income Before Tax Ratio | 17.69% | 24.20% | 24.36% | 19.98% | 21.12% | 22.06% | 23.12% | 27.55% | 27.39% | 27.66% | 21.69% | 20.49% | 19.01% | 27.52% | 25.45% | 26.56% | 21.74% | 27.36% | 27.03% | 27.11% | 24.62% | 25.60% | 23.93% | 22.73% | 20.94% | 18.05% | 20.22% | 18.65% | 17.60% | 17.04% | 16.49% | 16.05% | 16.37% | 14.45% | 15.52% | 15.51% | 14.89% | 5.58% | 14.00% |
| Income Tax Expense | 1.74B | 2.99B | 1.38B | 1.78B | 2.21B | 2.70B | 16.37B | 3.26B | 3.79B | 4.24B | 1.64B | 3.26B | 2.69B | 3.61B | 3.49B | 3.98B | 2.71B | 3.53B | 3.25B | 4.33B | 3.11B | 2.69B | 2.23B | 1.82B | 1.59B | 1.21B | 1.27B | 1.15B | 914.00M | 675.00M | 545.00M | 582.00M | 577.00M | 480.00M | 432.00M | 422.00M | 360.00M | 61.30M | 285.50M |
| Net Income | 35.15B | 17.94B | 20.88B | 14.71B | 15.12B | 15.30B | 1.30B | 16.54B | 15.41B | 16.32B | 13.83B | 10.85B | 9.67B | 13.33B | 12.27B | 12.95B | 10.58B | 11.05B | 10.41B | 8.51B | 7.20B | 6.60B | 5.67B | 4.80B | 4.17B | 3.06B | 3.30B | 2.89B | 2.40B | 2.01B | 1.79B | 1.03B | 1.46B | 1.14B | 1.08B | 974.00M | 833.00M | 329.50M | 613.70M |
| Net Income Ratio | 41.28% | 22.43% | 26.52% | 17.82% | 18.42% | 18.75% | 1.70% | 23.01% | 21.99% | 21.96% | 19.40% | 16.14% | 14.87% | 21.65% | 19.82% | 20.31% | 17.31% | 20.73% | 20.61% | 17.97% | 17.19% | 18.17% | 17.17% | 16.47% | 15.17% | 12.93% | 14.60% | 13.35% | 12.75% | 12.75% | 12.64% | 7.49% | 11.74% | 10.18% | 11.09% | 10.82% | 10.40% | 4.71% | 9.56% |
| EPS | 13.88 | 6.86 | 7.93 | 5.59 | 5.74 | 5.75 | 0.48 | 6.08 | 5.57 | 5.86 | 4.90 | 3.91 | 3.54 | 4.86 | 4.45 | 4.67 | 3.67 | 3.76 | 3.38 | 2.75 | 2.42 | 2.20 | 1.87 | 1.65 | 1.43 | 1.08 | 1.24 | 1.09 | 0.93 | 0.78 | 0.69 | 0.17 | 0.55 | 0.43 | 0.41 | 0.36 | 0.31 | 0.12 | 0.21 |
| EPS Diluted | 13.73 | 6.73 | 7.81 | 5.51 | 5.63 | 5.61 | 0.47 | 5.93 | 5.48 | 5.70 | 4.81 | 3.86 | 3.49 | 4.78 | 4.40 | 4.57 | 3.63 | 3.73 | 3.35 | 2.74 | 2.29 | 2.16 | 1.84 | 1.61 | 1.39 | 1.06 | 1.21 | 1.09 | 0.93 | 0.78 | 0.68 | 0.16 | 0.54 | 0.43 | 0.40 | 0.35 | 0.31 | 0.12 | 0.21 |
| Weighted Avg Shares Out | 2.53B | 2.61B | 2.63B | 2.63B | 2.63B | 2.66B | 2.68B | 2.71B | 2.76B | 2.78B | 2.82B | 2.78B | 2.72B | 2.74B | 2.76B | 2.81B | 2.88B | 2.94B | 2.98B | 2.97B | 2.97B | 3.00B | 3.03B | 2.99B | 2.99B | 2.78B | 2.67B | 2.66B | 2.58B | 2.57B | 2.61B | 2.63B | 2.66B | 2.66B | 2.67B | 2.74B | 2.73B | 2.75B | 2.92B |
| Weighted Avg Shares Out (Dil) | 2.56B | 2.66B | 2.67B | 2.67B | 2.68B | 2.73B | 2.75B | 2.79B | 2.81B | 2.86B | 2.88B | 2.81B | 2.78B | 2.79B | 2.79B | 2.84B | 2.91B | 2.96B | 3.00B | 2.99B | 3.14B | 3.05B | 3.08B | 3.10B | 3.07B | 2.83B | 2.74B | 2.73B | 2.58B | 2.61B | 2.63B | 2.63B | 2.71B | 2.69B | 2.71B | 2.78B | 2.73B | 2.75B | 2.92B |
Johnson & Johnson Enters Oversold Territory
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator...
5 Relatively Secure And Cheap Dividend Stocks - November 2024: Yields Up To 9%
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering large discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than...
Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO® / DARZALEX® as subcutaneous monotherapy for high-risk smoldering multiple myeloma
If approved, DARZALEX FASPRO ® will become the first treatment option for patients with smoldering multiple myeloma at high-risk of developing multiple myeloma, offering a novel approach to treat before the onset of active disease and the occurrence of end...
Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO®/DARZALEX® (daratumumab) as subcutaneous monotherapy for high-risk smouldering multiple myeloma
If approved, daratumumab will become the first treatment option for patients with smouldering multiple myeloma at high-risk of developing multiple myeloma, offering a novel approach to treat before the onset of active disease and the occurrence of end organ damage1
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever
You'll also like these stocks for their track record of earnings growth.
My Top 10 High Dividend Yield Companies For November 2024: 2 Yield More Than 8%
I will highlight 10 high dividend yield companies which, I believe, are worth considering investing in for November 2024. Each company could increase your portfolio's ability to generate dividend income due to having an elevated Dividend Yield. I believe that...
US FDA approves Johnson & Johnson's device for heart condition
The U.S. Food & Drug Administration has approved Johnson & Johnson's device for a type of heart condition, the company said on Thursday.
Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024
New data for investigational nipocalimab in Sjögren's Disease (SjD) and new research on the impact of TREMFYA® (guselkumab) in psoriatic arthritis (PsA) will be highlighted across three oral sessions and a plenary session Results from the Phase 2 DAHLIAS study...
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
2 Great Dividend Aristocrats to Buy in November
Dividend Aristocrats represent a wide range of stocks in different industries, but each of these companies holds one characteristic in common: their management teams have raised their dividend distributions each year for more than 25 years.
Source: https://incomestatements.info
Category: Stock Reports